For older adults with hardened arteries who are already taking statins to lower their bad cholesterol, adding a common supplement called niacin doesn’t make the plaque in their neck arteries shrink any more than statins alone—even though it raises their good cholesterol.
Scientific Claim
In adults aged 65 and older with established atherosclerosis and LDL cholesterol already controlled to below 2.6 mmol/L with statin therapy, adding 1500 mg daily of extended-release niacin for 18 months does not significantly increase the rate of carotid artery plaque regression compared to statin therapy alone, despite raising HDL cholesterol by 17%.
Original Statement
“There was no difference in the rate of regression between groups (p=0.49).”
Evidence Quality Assessment
Claim Status
appropriately stated
Study Design Support
Design supports claim
Appropriate Language Strength
definitive
Can make definitive causal claims
Assessment Explanation
As a double-blind, randomized controlled trial with MRI-measured structural outcomes, this study design supports definitive causal language. The null result is accurately reported with appropriate statistical confidence.
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.
Systematic Review & Meta-AnalysisLevel 1aWhether adding niacin to statins reduces carotid or coronary plaque regression across multiple high-quality RCTs in older adults with controlled LDL.
Whether adding niacin to statins reduces carotid or coronary plaque regression across multiple high-quality RCTs in older adults with controlled LDL.
What This Would Prove
Whether adding niacin to statins reduces carotid or coronary plaque regression across multiple high-quality RCTs in older adults with controlled LDL.
Ideal Study Design
A systematic review and meta-analysis of all double-blind, placebo-controlled RCTs using serial MRI or intravascular ultrasound to measure carotid or coronary plaque volume in adults ≥65 years with established atherosclerosis and LDL <2.6 mmol/L on statins, comparing statin + niacin (≥1500 mg/day) vs. statin alone, with minimum 12-month follow-up and standardized imaging protocols.
Limitation: Cannot establish causation in individual patients or account for unmeasured confounders across trials.
Randomized Controlled TrialLevel 1bIn EvidenceCausal effect of niacin on plaque regression in this specific population when LDL is controlled.
Causal effect of niacin on plaque regression in this specific population when LDL is controlled.
What This Would Prove
Causal effect of niacin on plaque regression in this specific population when LDL is controlled.
Ideal Study Design
A multicenter, double-blind, placebo-controlled RCT of 500+ adults aged 65–85 with documented atherosclerosis and LDL <2.6 mmol/L on stable statin therapy, randomized to extended-release niacin 1500 mg/day or placebo for 24 months, with primary outcome measured by serial carotid MRI plaque volume and secondary outcomes including lipid profiles and vascular inflammation markers.
Limitation: Limited to structural outcomes; cannot prove impact on clinical events like stroke or heart attack.
Prospective Cohort StudyLevel 2bLong-term association between niacin use and plaque progression/regression in real-world older adults with controlled LDL.
Long-term association between niacin use and plaque progression/regression in real-world older adults with controlled LDL.
What This Would Prove
Long-term association between niacin use and plaque progression/regression in real-world older adults with controlled LDL.
Ideal Study Design
A prospective cohort of 2000+ adults aged 65+ with atherosclerosis and LDL <2.6 mmol/L on statins, tracked for 5 years with annual carotid MRI, comparing those who add niacin vs. those who do not, adjusting for adherence, comorbidities, and statin intensity.
Limitation: Cannot rule out selection bias or unmeasured confounders (e.g., diet, exercise).
Case-Control StudyLevel 3Whether prior niacin use is associated with less plaque progression in older adults who later experience cardiovascular events.
Whether prior niacin use is associated with less plaque progression in older adults who later experience cardiovascular events.
What This Would Prove
Whether prior niacin use is associated with less plaque progression in older adults who later experience cardiovascular events.
Ideal Study Design
A case-control study comparing 300 older adults (≥65) with documented carotid plaque progression (cases) to 300 matched controls without progression, assessing prior use of niacin (≥12 months) while controlling for statin use, LDL/HDL levels, and comorbidities.
Limitation: Retrospective design limits ability to establish temporal sequence or causality.
Evidence from Studies
Supporting (1)
MRI-measured regression of carotid atherosclerosis induced by statins with and without niacin in a randomised controlled trial: the NIA plaque study
The study gave older adults with heart disease either a niacin pill or a sugar pill, both on top of their statin. Even though niacin raised 'good' cholesterol, it didn’t make the artery plaques shrink any faster than the sugar pill did.